Risk Warning Announcement on Possible Termination of Listing for Company Stock and Convertible Bonds
Special Reminder:
-
Hainan Puli Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") received an "Administrative Penalty Decision" from the China Securities Regulatory Commission (hereinafter referred to as "CSRC") on March 21, 2025, which determined that the Company’s annual reports for 2021 and 2022 contained false disclosures. The total amount of falsely reported revenue for 2021 and 2022 reached 1,029,037,811.01 yuan, accounting for 31.04% of the total disclosed annual revenue for those two years; the total amount of falsely reported profit reached 669,242,029.68 yuan, accounting for 73.83% of the total disclosed annual profit for those two years. These facts trigger the major illegal circumstances for mandatory delisting as stipulated in Article 10.5.1 (1) and Article 10.5.2 (1)(7) of the "Shenzhen Stock Exchange GEM Stock Listing Rules (2024 Revision)," which states that if a company has false disclosures of total profit for two consecutive years, with the total amount exceeding 500 million yuan and more than 50% of the total disclosed annual profit for those two years, the company's stock may be terminated from listing.
-
According to Article 10.5.8 of the "GEM Stock Listing Rules," the Company's stock and convertible bonds will be suspended from trading starting March 24, 2025.
-
According to Article 10.1.9 of the "GEM Stock Listing Rules" and the "Self-Regulatory Guidelines No. 15 for Listed Companies on the Shenzhen Stock Exchange - Convertible Bonds," if the listed company's stock is terminated from listing, the convertible bonds (hereinafter referred to as "convertible bonds") will also be terminated from listing or quotation simultaneously.